Batrafen Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

batrafen

sanofi-aventis new zealand limited - ciclopirox olamine 1%{relative} - topical cream - 1% w/w - active: ciclopirox olamine 1%{relative}

Batrafen Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

batrafen

sanofi-aventis new zealand limited - ciclopirox olamine 1%{relative} - topical solution - 1% w/v - active: ciclopirox olamine 1%{relative}

Intal Forte Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

intal forte

sanofi-aventis new zealand limited - sodium cromoglicate 5mg equivalent to 3.5211% w/w;  ;   - aerosol inhaler, metered dose - 5 mg/dose - active: sodium cromoglicate 5mg equivalent to 3.5211% w/w     excipient: apaflurane macrogol 600 povidone - intal forte 5 mg cfc-free is indicated for the preventive treatment of bronchial asthma (which may be due to allergy, exercise, cold air or chemical irritants) in adults and children.

Tilade CFC-free Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

tilade cfc-free

sanofi-aventis new zealand limited - nedocromil sodium 1.4085%{relative} (2 mg/dose);   - aerosol inhaler, metered dose - 2 mg/dose - active: nedocromil sodium 1.4085%{relative} (2 mg/dose)   excipient: apaflurane macrogol 600 menthol povidone - tilade cfc-free is indicated in the treatment of bronchial asthma (whether extrinsic or intrinsic in nature, and including asthmatic bronchitis, late onset asthma, exercise induced asthma, and bronchospasm provoked by a variety of stimuli such as cold air, inhaled allergens, atmospheric pollutants and other irritants). tilade cfc-free is intended for regular prophylactic treatment and not for symptomatic relief. in the management of asthma, tilade cfc-free improves pulmonary function, reduces the frequency and severity of attacks and reduces bronchospasm, cough and bronchial hyper-responsiveness. in patients already receiving treatment for their asthma, tilade cfc-free can be given in addition to all existing therapies and will in many cases provide added therapeutic benefit. having established this benefit of tilade cfc-free, it may be possible to gradually reduce or eliminate concomitant therapy.

Apidra SoloStar 100 Unitsml Solution for injection in a pre-filled pen Сингапур - Енглески - HSA (Health Sciences Authority)

apidra solostar 100 unitsml solution for injection in a pre-filled pen

sanofi-aventis singapore pte. ltd. - insulin glulisine - injection, solution - 3.49 mg (100 units) - insulin glulisine 3.49 mg (100 units)

Lantus SoloStar 100 Unitsml Solution for injection in a pre-filled pen Сингапур - Енглески - HSA (Health Sciences Authority)

lantus solostar 100 unitsml solution for injection in a pre-filled pen

sanofi-aventis singapore pte. ltd. - insulin glargine - injection, solution - 100 iu/ml - insulin glargine 100 iu/ml

LYXUMIA SOLUTION FOR INJECTION IN PRE-FILLED PEN 10MCG (50mcgmL) Сингапур - Енглески - HSA (Health Sciences Authority)

lyxumia solution for injection in pre-filled pen 10mcg (50mcgml)

sanofi-aventis singapore pte. ltd. - lixisenatide - injection, solution - 50mcg/ml - lixisenatide 50mcg/ml

LYXUMIA SOLUTION FOR INJECTION IN PRE-FILLED PEN 10MCG AND 20MCG (50mcgmL and 100mcgmL) Сингапур - Енглески - HSA (Health Sciences Authority)

lyxumia solution for injection in pre-filled pen 10mcg and 20mcg (50mcgml and 100mcgml)

sanofi-aventis singapore pte. ltd. - (10mcg) lixisenatide; (20mcg) lixisenatide - injection, solution - 0.05mg/ml - (10mcg) lixisenatide 0.05mg/ml; (20mcg) lixisenatide 0.1mg/ml

LYXUMIA SOLUTION FOR INJECTION IN PRE-FILLED PEN 20MCG (100mcgmL) Сингапур - Енглески - HSA (Health Sciences Authority)

lyxumia solution for injection in pre-filled pen 20mcg (100mcgml)

sanofi-aventis singapore pte. ltd. - lixisenatide - injection, solution - 100mcg/ml - lixisenatide 100mcg/ml

APIDRA 100 Unitsml Solution for Injection in vial Сингапур - Енглески - HSA (Health Sciences Authority)

apidra 100 unitsml solution for injection in vial

sanofi-aventis singapore pte. ltd. - insulin glulisine - injection, solution - 3.49 mg - insulin glulisine 3.49 mg